Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study
-
Published:2024-04
Issue:
Volume:
Page:
-
ISSN:2588-9311
-
Container-title:European Urology Oncology
-
language:en
-
Short-container-title:European Urology Oncology
Author:
Massari Francesco, Mollica VeronicaORCID, Fiala Ondrej, De Giorgi Ugo, Kucharz Jakub, Vitale Maria Giuseppa, Molina-Cerrillo Javier, Facchini Gaetano, Seront Emmanuel, Lenci Edoardo, Bourlon Maria T., Carrozza Francesco, Pichler Renate, Lolli Cristian, Myint Zin W., Kanesvaran Ravindran, Torniai Mariangela, Rescigno Pasquale, Gomez de Liaño Alfonso, Zakopoulou Roubini, Buti Sebastiano, Porta Camillo, Grande Enrique, Santoni Matteo
Reference25 articles.
1. Non-clear cell renal carcinomas: review of new molecular insights and recent clinical data;Barthélémy;Cancer Treat Rev,2021 2. WHO Classification of Tumours Editorial Board. Classification of tumours of the urinary and male genital systems. ed. 5. Lyon, France: IARC Press; 2022. 3. Comprehensive molecular characterization of papillary renal-cell carcinoma;The Cancer Genome Atlas Research Network;N Engl J Med,2016 4. WHO 2022 landscape of papillary and chromophobe renal cell carcinoma;Lobo;Histopathology,2022 5. Tateo V, Mollica V, Rizzo A, Santoni M, Massari F. Re: WHO classification of tumours, 5th edition, volume 8: urinary and male genital tumours. Eur Urol 2023;84:348-9. https://doi.org/10.1016/j.eururo.2023.04.030.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|